Investing

Corvus Pharmaceuticals : CRVS

CRVS

Stock Data

$14.10

$0.80 (5.37%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.

All Corvus Pharmaceuticals Articles

5 Articles

Rich Duprey | Jun 11, 2025 at 9:27 AM EDT

3 Penny Stocks Wall Street Sees With 243% Upside

Penny stocks captivate investors with their low prices. The allure of controlling large numbers of shares for relatively very little…

Lee Jackson | Aug 22, 2023 at 8:55 AM EDT

Tuesday’s Top Wall Street Upgrades and Downgrades: Applied Materials, CVS Health, Hawaiian Electric Industries, Walmart and More

Tuesday's top analyst upgrades and downgrades included Applied Materials, Bill, Catalyst Pharmaceutical, CVS Health, Elastic, Hawaiian Electric Industries and Walmart.

Lee Jackson | Dec 4, 2021 at 6:10 AM EST

5 White-Hot Stocks Trading Under $10 to Buy Now Have Great Upside Potential

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential.…

Chris Lange | Dec 1, 2021 at 12:05 PM EST

Wednesday Afternoon’s Analyst Upgrades and Downgrades: Lennar, StoneCo, Vertex Energy and More

Wednesday afternoon's analyst upgrades and downgrades included American Water Works, Corvus Pharmaceuticals, ImmunoGen, Lennar, StoneCo and Vertex Energy.

Lee Jackson | Feb 10, 2021 at 8:57 AM EST

Top Analyst Upgrades and Downgrades: Akamai, Avaya, Canopy Growth, Corsair Gaming, Playtika, Virgin Galactic and More

Wednesday's top analyst upgrades and downgrades included Akamai Technologies, Avaya, Canopy Growth, Corsair Gaming, Skyworks Solutions and Virgin Galactic.